Figure 2.
The baseline tumor FES (left) and percent change in tumor FDG (right) uptake after estradiol challenge in patients who responded and who did not respond to endocrine therapy.
The baseline tumor FES (left) and percent change in tumor FDG (right) uptake after estradiol challenge in patients who responded and who did not respond to endocrine therapy.